|
Skyepharma banking on European approval for Flutiform
Stock Market Wire The group said it was counting on European approval of asthma treatment Flutiform and launch in the second half of 2011. Revenue was up 4% to £58.1m from £55.9m, in line with management expectations. The rise was primarily due to a substantial increase … SkyePharma Moves To 2010 Pretax Profit, Sees Cash Outflows STOCKS NEWS UK-SkyePharma up on results Flutiform optimism Skyepharma turns in annual profit |
View full post on asthma – Google News